Kiora Pharmaceuticals

Retinitis pigmentosa
#Clinical trial #Kiora Pharmaceuticals #Ophthalmology #Phase I trial #Retinitis pigmentosa

Molecular photoswitch improves visual acuity in retinitis pigmentosa

Topline results from a Phase I/II clinical trial have shown that Kiora’s light-restoring small molecule KIO-301 has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP). The results of the ABACUS study for Kiora’s intravitreal (IVT) molecular photoswitch were presented at the American… Read More

#News